Background: The purpose of the study was to compare the efficacy of Isoxsuprine and Nifedipine as tocolytic agent on preterm labour and to compare the Obstetrical outcome following Isoxsuprine and Nifedipine therapy as a tycolytic agent. Methods: The study which was randomized prospective study, comprised of 100 patients with preterm labor, admitted in antenatal ward of State Referral Hospital, Falkawn, Mizoram during the period of January 2015 to December 2017. The Patients who fullfield the inclusion criteria for the study were divided into 2 groups; group-A consisted of 48 patients, treated with Nifedipine for tocolysis, the group-B consisted of 52 patients, who received isoxsuprine for tocolysis, and were monitored throughout the course of treatment. Result: Successful tocolysis was achieved by Nifedipine in 77.1% of the case as compared to 67% with the isoxsuprine treated cases. And Nifedipine prolonged pregnancy for 15.427±12.875 days while Isoxsuprine prolonged pregnancy for 13.356±13.612 days. Apgar score of babies less than 7 was 33.3% in Group-A and 32.6% in Group-B. The incidence of perinatal death (16%) in group-A is lower as compared to (19.6%) group-B. Conclusion: Nifedipine is more effective tocolytic agent, as compared to Isoxsuprine. The neonatal outcome with respect to birth weight, Apgar score and perinatal death were better in the cases treated with nifedipine as compared to Isoxsuprine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.